6-APDB

6-APDB
Clinical data
Other names	6-(2-Aminopropyl)-2,3-dihydrobenzofuran; 4-Desoxy-MDA; EMA-3; BF6AP
Routes of; administration	Oral
Drug class	Entactogen; Stimulant
ATC code	None;
Legal status
Legal status	CA: Schedule I; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine;
CAS Number	152623-93-3 ;
PubChem CID	192599;
ChemSpider	167141 ;
UNII	O72F3CP4O8;
ChEMBL	ChEMBL124055 ;
CompTox Dashboard (EPA)	DTXSID60934559 ;
Chemical and physical data
Formula	C11H15NO
Molar mass	177.247 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O2c1cc(ccc1CC2)CC(N)C;
	InChI InChI=1S/C11H15NO/c1-8(12)6-9-2-3-10-4-5-13-11(10)7-9/h2-3,7-8H,4-6,12H2,1H3 ; Key:VRNGXHJGMCJRSQ-UHFFFAOYSA-N ;
	(what is this?) (verify)

6-APDB, also known as 6-(2-aminopropyl)-2,3-dihydrobenzofuran or as 4-desoxy-MDA, is an entactogen of the phenethylamine, amphetamine, and dihydrobenzofuran families. It is an analogue of MDA where the heterocyclic 4-position oxygen from the 3,4-methylenedioxy ring has been replaced with a methylene bridge. 5-APDB (3-desoxy-MDA) is an analogue of 6-APDB where the 3-position oxygen has been replaced with a methylene instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic analogues of MDMA and first described in 1993.